Yes dissapointing today. We'd all expected to see a little more traction, but more importantly, hadn't expected to have been blindsided regarding not even being a part of Covius telehealth business due to the switch in platform.
Clearly need to play the long game. Tech still works, should be demand for the product at some point in the future. In theory we are now one quarter closer to that point.
Ann: AstraZeneca to use new ResApp software in study - Revised, page-15
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)